Amgen Inc. (NASDAQ:AMGN) Shares Sold by Marks Group Wealth Management Inc

Marks Group Wealth Management Inc reduced its holdings in Amgen Inc. (NASDAQ:AMGN) by 5.3% during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 5,939 shares of the medical research company’s stock after selling 331 shares during the period. Marks Group Wealth Management Inc’s holdings in Amgen were worth $1,548,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds have also made changes to their positions in AMGN. AMF Tjanstepension AB grew its position in shares of Amgen by 16.9% in the third quarter. AMF Tjanstepension AB now owns 120,389 shares of the medical research company’s stock valued at $38,825,000 after purchasing an additional 17,387 shares during the period. Creative Planning lifted its stake in Amgen by 8.6% in the 3rd quarter. Creative Planning now owns 197,457 shares of the medical research company’s stock valued at $63,402,000 after buying an additional 15,564 shares in the last quarter. Swedbank AB boosted its holdings in Amgen by 1.1% in the 3rd quarter. Swedbank AB now owns 538,899 shares of the medical research company’s stock worth $173,639,000 after buying an additional 5,751 shares during the last quarter. Magnus Financial Group LLC increased its stake in Amgen by 15.2% during the 3rd quarter. Magnus Financial Group LLC now owns 896 shares of the medical research company’s stock worth $289,000 after buying an additional 118 shares in the last quarter. Finally, Regatta Capital Group LLC raised its holdings in shares of Amgen by 2.7% during the third quarter. Regatta Capital Group LLC now owns 6,083 shares of the medical research company’s stock valued at $1,960,000 after acquiring an additional 159 shares during the last quarter. 76.50% of the stock is currently owned by hedge funds and other institutional investors.

Amgen Trading Down 0.5 %

NASDAQ AMGN opened at $295.06 on Thursday. The company has a debt-to-equity ratio of 9.62, a current ratio of 1.26 and a quick ratio of 0.96. The stock has a market capitalization of $158.60 billion, a P/E ratio of 39.08, a PEG ratio of 3.01 and a beta of 0.56. The firm’s 50-day moving average is $272.96 and its two-hundred day moving average is $302.23. Amgen Inc. has a 12 month low of $253.30 and a 12 month high of $346.85.

Amgen (NASDAQ:AMGN) last issued its quarterly earnings data on Tuesday, February 4th. The medical research company reported $5.31 EPS for the quarter, topping the consensus estimate of $5.04 by $0.27. Amgen had a net margin of 12.24% and a return on equity of 176.32%. On average, sell-side analysts anticipate that Amgen Inc. will post 20.59 earnings per share for the current year.

Amgen Increases Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Friday, March 7th. Stockholders of record on Friday, February 14th will be paid a $2.38 dividend. The ex-dividend date is Friday, February 14th. This is a boost from Amgen’s previous quarterly dividend of $2.25. This represents a $9.52 dividend on an annualized basis and a dividend yield of 3.23%. Amgen’s payout ratio is presently 119.21%.

Insider Activity at Amgen

In other Amgen news, SVP Nancy A. Grygiel sold 1,589 shares of the business’s stock in a transaction on Wednesday, February 5th. The shares were sold at an average price of $304.47, for a total value of $483,802.83. Following the completion of the transaction, the senior vice president now owns 7,210 shares in the company, valued at $2,195,228.70. The trade was a 18.06 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at the SEC website. Also, EVP Jonathan P. Graham sold 25,045 shares of the stock in a transaction on Friday, February 7th. The shares were sold at an average price of $293.12, for a total value of $7,341,190.40. Following the completion of the sale, the executive vice president now owns 28,987 shares in the company, valued at approximately $8,496,669.44. The trade was a 46.35 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Company insiders own 0.69% of the company’s stock.

Analyst Ratings Changes

AMGN has been the topic of a number of research analyst reports. Leerink Partners lowered their price target on Amgen from $349.00 to $302.00 in a research note on Wednesday, November 27th. StockNews.com lowered shares of Amgen from a “strong-buy” rating to a “buy” rating in a report on Wednesday, December 18th. TD Cowen increased their target price on shares of Amgen from $381.00 to $383.00 and gave the company a “buy” rating in a research report on Monday, October 21st. Royal Bank of Canada restated an “outperform” rating and set a $324.00 price target on shares of Amgen in a research report on Friday, January 24th. Finally, Redburn Partners cut their price objective on shares of Amgen from $200.00 to $195.00 in a report on Wednesday, November 27th. Two investment analysts have rated the stock with a sell rating, ten have assigned a hold rating, twelve have given a buy rating and one has given a strong buy rating to the stock. Based on data from MarketBeat, the company presently has a consensus rating of “Hold” and an average target price of $314.09.

Amgen Company Profile

Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout.